The Effects of Aripiprazole on the Processing of Rewards in Schizophrenia
The objective of this study is to determine whether subjects with negative symptoms of schizophrenia have abnormal functioning of brain circuits relevant to reward processing, and to determine whether any such abnormalities are normalized by treatment with aripiprazole.
|Study Design:||Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: Open Label
|Official Title:||Aripiprazole Effects on Reward Processing in Deficit Syndrome Schizophrenia|
- BOLD Activation During fMRI Scanning During Performance of a Monetary Reward Task [ Time Frame: Baseline and 12 weeks ] [ Designated as safety issue: No ]fMRI BOLD activation during a reward task will be compared between schizophrenia subjects and controls at Baseline. Schizophrenia subjects will switch their baseline medication to aripiprazole and their BOLD activation during the reward task at Baseline will be compared to the endpoint scan.
|Study Start Date:||April 2005|
|Study Completion Date:||April 2011|
|Primary Completion Date:||December 2010 (Final data collection date for primary outcome measure)|
Experimental: schizophrenia subjects
Patients to be switched from baseline medication to aripiprazole, and fMRI measured at baseline and after med switch.
fMRI scanning during behavioral reward taskDrug: Aripiprazole
30 mg by mouth once daily
Show Detailed Description
Please refer to this study by its ClinicalTrials.gov identifier: NCT00209027
|United States, Georgia|
|Atlanta VA Medical Center|
|Decatur, Georgia, United States, 30033|
|Principal Investigator:||Erica Duncan, MD||Emory University/Atlanta VA Medical Center|